Novartis and Genentech push for clarity from FDA on how disease progression models can be used for regulatory decisions
As companies continue their search for new drugs for debilitating diseases that progress over years and are notoriously tough to crack (think Alzheimer’s disease), the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
